Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
mechanism of action of glp 1 receptor agonist Therapeutic Potential GLP-1 Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications | Cardiovascular Drugs and Therapy Glucagon Receptor Agonist Merck pays $112M upfront Type:Paperback
Merck pays $112M upfront for Hansoh's preclinical GLP-1
Ideal candidates typically: Have struggled with weight control despite lifestyle modification Display signs of insulin resistance or metabolic syndrome Require medical assistance to prevent progression of obesity-related diseases Exclusion criteria may include individuals with a history of certain endocrine disorders, pancreatitis, or specific gastrointestinal diseases
Glucagon Receptor Agonist
Type:Paperback
34 (4), e2982
US$ 20.58
US$ 27.22
US$ 27.67
